Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000810283 | SCV000950476 | uncertain significance | Seizures, benign familial infantile, 3; Developmental and epileptic encephalopathy, 11 | 2022-06-08 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 654341). This variant has not been reported in the literature in individuals affected with SCN2A-related conditions. This variant is present in population databases (rs759697991, gnomAD 0.0009%). This sequence change replaces lysine, which is basic and polar, with asparagine, which is neutral and polar, at codon 1804 of the SCN2A protein (p.Lys1804Asn). |
Revvity Omics, |
RCV003141820 | SCV003820762 | uncertain significance | not provided | 2021-03-26 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004962832 | SCV005500045 | uncertain significance | Inborn genetic diseases | 2024-09-09 | criteria provided, single submitter | clinical testing | The c.5412G>T (p.K1804N) alteration is located in exon 27 (coding exon 26) of the SCN2A gene. This alteration results from a G to T substitution at nucleotide position 5412, causing the lysine (K) at amino acid position 1804 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |